Sotatercept for the Treatment of Pulmonary Arterial Hypertension
نویسندگان
چکیده
Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling associated with both hereditary idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins growth differentiation factors in the attempt to restore balance between growth-promoting growth-inhibiting pathways.
منابع مشابه
THE EFFECTS OF CAPTOPRIL ON PULMONARY AND SYS TEMIC ARTERIAL PRESSURES IN HIGHALTITUDE PULMONARY HYPERTENSION
The purpose of this investigation was to assess the effect of captopril on both systemic (P.a) and pulmonary arterial pressures (PPA) in patients with high-altitude pulmonary hypertension (HAPH). Seventeen patients (mean age 44±6.8 years) with HAPH and mild to moderate systemic arterial hypertension were included in the study. All patients underwent right heart catheterization with measurem...
متن کاملTreatment of pulmonary arterial hypertension.
the authors reply: Arias et al. correctly note that diabetes is an independent risk factor for congestive heart failure. Data from the Cardiovascular Health Study have also shown a significant independent relationship between diabetes and the development of congestive heart failure1; most cases of heart failure in that cohort were associated with a normal or near-normal ejection fraction — that...
متن کاملTreatment of pulmonary arterial hypertension.
Patients with pulmonary arterial hypertension (PAH) must be referred to expert centers (reference center and competences centers in the French PAH network). Despite progresses in the knowledge of PAH pathophysiology, it is still a devastating disease needing an aggressive approach of therapy to improve long-term outcomes. The target of current therapies is endothelial dysfunction of pulmonary a...
متن کاملTreatment of pulmonary arterial hypertension.
OBJECTIVE To perform a review of the diagnostic and therapeutic management of pulmonary hypertension in the pediatric population, with emphasis on pharmacological factors. SOURCES Electronic search of publications on the MEDLINE/PubMed, LILACS and Cochrane Collaboration databases. The search strategy adopted gave priority to the identification of clinical trials (controlled or uncontrolled), ...
متن کاملThe pharmacological treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a life-threatening and progressive disease of various origins characterized by pulmonary vascular remodeling that leads to increased pulmonary vascular resistance and pulmonary arterial pressure, most often resulting in right-sided heart failure. The most common symptom at presentation is breathlessness, with impaired exercise capacity as a hallmark of t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The New England Journal of Medicine
سال: 2021
ISSN: ['0028-4793', '1533-4406']
DOI: https://doi.org/10.1056/nejmoa2024277